High-throughput screen identifies novel inhibitors of cancer biomarker α-methylacyl coenzyme A racemase (AMACR/P504S)

Molecular Cancer Therapeutics

Volumn 10, Issue 5, 2011, Pages 825-838

  Wilson, Brice A P ^a   Wang, Haofan ^a   Nacev, Benjamin A ^a   Mease, Ronnie C ^a   Liu, Jun O ^a   Pomper, Martin G ^a   Isaacs, William B ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2,5 DIHYDROXY 4 METHYLPHENYL) 5 METHYL BENZENE 1.4 DIOL; 2 METHYLACYL COENZYME A RACEMASE; 2 METHYLSULFANYL 7,9 DIHYDRO 3H PURINE 6,8 DITHIONE; 2,5 DI(PYRAZOL 1 YL)BENZENE 1,4 DIOL; 3,5 DI(PYRIDIN 4 YL) 1,2,4 THIADIAZOLE; 3,7,12 TRIHYDROXYCHOLESTANOYL COENZYME A; CONGO RED; EBSELEN; EBSELEN OXIDE; ENZYME INHIBITOR; ROSE BENGAL; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CONTROLLED STUDY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; FIBROBLAST; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION;

AZOLES; CELL LINE, TUMOR; ENZYME INHIBITORS; GENE KNOCKDOWN TECHNIQUES; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; KINETICS; ORGANOSELENIUM COMPOUNDS; RACEMASES AND EPIMERASES; REPRODUCIBILITY OF RESULTS; RNA, SMALL INTERFERING; SMALL MOLECULE LIBRARIES; TUMOR MARKERS, BIOLOGICAL;

EID: 79955984121     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0902     Document Type: Article

References (48)

1. Schmitz W, Albers C, Fingerhut R, Conzelmann E. Purification and characterization of an α-methylacyl-CoA racemase from human liver. Eur J Biochem 1995;231:815-22.
2. Schmitz W, Fingerhut R, Conzelmann E. Purification and properties of an alpha-methylacyl-CoA racemase from rat liver. Eur J Biochem 1994;222:313-23.
3. Darley DJ, Butler DS, Prideaux SJ, Thornton TW, Wilson AD, Woodman TJ, et al. Synthesis and use of isotope-labelled substrates for a mechanistic study on human α-methylacyl-CoA racemase 1A (AMACR; P504S). Org Biomol Chem 2009;7:543-52.
4. Ouazia D, Bearne SL. A continuous assay for α-methylacyl-coenzyme A racemase using circular dichroism. Anal Biochem 2010;398: 45-51.
5. Sattar FA, Darley DJ, Politano F, Woodman TJ, Threadgill MD, Lloyd MD. Unexpected stereoselective exchange of straight-chain fatty acyl-CoA α-protons by human a-methylacyl-CoA racemase 1A (P504S). Chem Commun 2010;46:3348-50.
6. Cuebas DA, Phillips C, Schmitz W, Conzelmann E, Novikov DK. The role of alpha-methylacyl-CoA racemase in bile acid synthesis. Biochem J 2002;363(Pt 3):801-7. (Pubitemid 34526402)
7. Salvolainen K, Bhaumik P, Schmitz W, Kotti TJ, Conzelmann E, Wierenga RK, et al. α -Methylacyl-CoA racemase from Mycobacterium tuberculosis: mutational and structural characterization of the active site and the fold. J Biol Chem 2004;280:12611-20.
8. Bhaumik P, Schmitz W, Hassinen A, Hiltunen JK, Conzelmann E, Wierenga RK. The catalysis of the 1, 1-proton transfer by [alpha]-methyl-acyl-CoA racemase is coupled to a movement of the fatty acyl moiety over a hydrophobic, methionine-rich surface. J Mol Biol 2007;367:1145-61. (Pubitemid 46386079)
9. Ferdinandusse S, Denis S, Clayton PT, Graham A, Rees JE, Allen JT, et al. Mutations in the gene encoding peroxisomal a-methylacyl-CoA racemase cause adult-onset sensory motor neuropathy. Nat Genet 2000;24:188-91. (Pubitemid 30094723)
10. Xu J, Stolk JA, Zhang X, Silva SJ, Houghton RL, Matsumura M , et al. Identification of differentially expressed genes in human prostate cancer using subtraction and microarray. Cancer Res 2000;60: 1677-82. (Pubitemid 30183441)
11. Luo J, Zha S, Gage WR, Dunn TA, Hicks JL, Bennett CJ, et al. a-Methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res 2002;62:2220-6. (Pubitemid 34411693)
12. Goldstein AS, Huang J, Guo C, Garraway IP, Witte ON. Identification of a cell of origin for human prostate cancer. Science 2010;329:568-71.
13. Rubin MA, Zhou M, Dhanasekaran SM, Varambally S, Barrette TR, Sanda MG, et al. α-methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 2002;287:1662-70. (Pubitemid 34289218)
14. Zha S, Ferdinandusse S, Denis S, Wanders RJ, Ewing CM, Luo J, et al. a-methylacyl-CoA racemase as an androgen-independent growth modifier in prostate cancer. Cancer Res 2003;63:7365-76. (Pubitemid 37413478)
15. Kumar-Sinha C, Shah RB, Laxman B, Tomlins SA, Harwood J, Schmitz W, et al. Elevated a-methylacyl-CoA racemase enzymatic activity in prostate cancer. Am J Pathol 2004;164:787-93. (Pubitemid 38235461)
16. Takahara K, Azuma H, Sakamoto T, Kiyama S, Inamoto T, Ibuki N , et al. Conversion of prostate cancer from hormone independency to dependency due to AMACR inhibition: involvement of increased AR expression and decreased IGF1 expression. Anticancer Res 2009;29:2497-505.
17. Savolainen K, Kotti TJ, Schmitz W, Savolainen TI, Sormunen RT, Ilves M, et al. A mouse model for a-methylacyl-CoA racemase deficiency: adjustment of bile acid synthesis and intolerance to dietary methylbranched lipids. Hum Mol Genet 2004;13:955-65. (Pubitemid 38628431)
18. Zhou M, Chinnaiyan AM, Kleer CG, Lucas PC, Rubin MA. Alpha-methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions. Am J Surg Pathol 2002;26:926-31. (Pubitemid 34747646)
19. Zlatopolskiy B, Morgenroth A, Urusova E, Kunkel FH, Dinger C, Kull T, et al. IVC-11: a tracer for targeting of a-methylacyl-CoA racemase (AMACR). J Nucl Med 2009;50:1913
20. Zaheer A, Cho SY, Pomper MG. New agents and techniques for imaging prostate cancer. J Nucl Med 2009;50:1387-90.
21. Turkbey B, Albert PS, Kurdziel K, Choyke PL. Imaging localized prostate cancer: current approaches and new developments. Am J Roentgenol 2009;192:1471-80.
22. Edwards BK, Ward E, Kohler BA, Eheman C, Zauber AG, Anderson RN, et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 2010;116:544-73.
23. Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst 2009;101:1325-9.
24. Brawley OW. Prostate cancer sreening; is this a teachable moment?J Natl Cancer Inst 2009;101:1295-7.
25. Van Veldhoven P, Croes K, Casteels M, Mannaerts G. 2-methylacyl racemase: a coupled assay based on the use of pristanoyl-CoA oxidase/peroxidase and reinvestigation of its subcellular distribution in rat and human liver. Biochim Biophys Acta 1997;1347:62-8. (Pubitemid 27281655)
26. Carnell AJ, Hale I, Denis S, Wanders RJ, Isaacs WB, Wilson BA, et al. Design, synthesis, and in vitro testing of α-methylacyl-CoA racemase inhibitors. J Med Chem 2007;50:2700-7.
27. Silverman RB. Mechanism-based enzyme inactivators. Enzyme kinetics and mechanism part D: developments in enzyme dynamics. San Diego: Academic Press; 1995p. 240-83.
28. Kitz R, Wilson IB. Esters of methanesulfonic acid as irreversible inhibitors of acetylcholinesterase. J Biol Chem 1962;237:3245-50.
29. Webber MM, Trakul N, Thraves PS, Bello-DeOcampo D, Chu WW, Storto PD, et al. A human prostatic stromal myofibroblast cell line WPMY-1: a model for stromal-epithelial interactions in prostatic neoplasia. Carcinogenesis 1999;20:1185-92. (Pubitemid 29341437)
30. Marco AD, Marcucci I, Verdirame M, Pérez J, Sanchez M, Peláez F, et al. Development and validation of a high-throughput radiometric CYP3A4/5 inhibition assay using tritiated testosterone. Drug Metabol Dispos 2005;33:349-58. (Pubitemid 40279934)
31. Di Marco A, Cellucci A, Chaudhary A, Fonsi M, Laufer R. High-throughput radiometric CYP2C19 inhibition assay using tritiated (S)-mephenytoin. Drug Metabol Dispos 2007;35:1737-43. (Pubitemid 47481564)
32. Chong CR, Chen X, Shi L, Liu JO, Sullivan DJ. A clinical drug library screen identifies astemizole as an antimalarial agent. Nat Chem Biol 2006;2:415-6. (Pubitemid 44114918)
33. Grillo FG, Aronson PS. Inactivation of the renal microvillus membrane Na+-H+ exchanger by histidine-specific reagents. J Biol Chem 1986;261:1120-5. (Pubitemid 16144775)
34. Walther M, Holzhutter HG, Kuban RJ, Wiesner R, Rathmann J, Kuhn H. The inhibition of mammalian 15-lipoxygenases by the anti-inflammatory drug ebselen: dual-type mechanism involving covalent linkage and alteration of the iron ligand sphere. Mol Pharmacol 1999;56:196-203. (Pubitemid 29309829)
35. Sakurai T, Kanayama M, Shibata T, Itoh K, Kobayashi A, Yamamoto M, Uchida K. Ebselen, a seleno-organic antioxidant, as an electrophile. Chem Res Toxicol 2006;19:1196-1204. (Pubitemid 44454036)
36. Weiser HB, Radcliffe RS. The physical chemistry of color lake formation. IV. Red Congo Acids and Red Congo Lakes. J Phys Chem 1928;32:1875-85.
37. Valdes-Aguilera O, Neckers DC. Aggregation of rose bengal ethyl ester induced by alkali metal cations in aqueous solution. J Photochem Photobiol A: Chem 1989;47:213-22.
38. Kuo DJ, Jordan F. Active site directed irreversible inactivation of brewers' yeast pyruvate decarboxylase by the conjugated substrate analog (E)-4-(4-chlorophenyl)-2-oxo-3-butenoic acid: development of a suicide substrate. Biochemistry 1983;22:3735-40.
39. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. The N Engl J Med 2009;360:1320-8.
40. Henderickx HJW, Duchateau ALL, Raemakers-Franken PC. Chiral liquid chromatography-mass spectrometry for high-throughput screening of enzymatic racemase activity. J Chromatogr A 2003;1020: 69-74. (Pubitemid 38367562)
41. Dixon SM, Li P, Liu R, Wolosker H, Lam KS, Kurth MJ, et al. Slow-binding human serine racemase inhibitors from high-throughput screening of combinatorial libraries. J Med Chem 2006;49:2388-97.
42. Bhabak K, Mugesh G. Synthesis, characterization, and antioxidant activity of some ebselen analogues. Chem Eur J 2007;13:4594-601. (Pubitemid 46925566)
43. Zhao R, Masayasu H, Holmgren A. Ebselen: a substrate for human thioredoxin reductase strongly stimulating its hydroperoxide reductase activity and a superfast thioredoxin oxidant. Proc Natl Acad Sci 2002;99:8579-84. (Pubitemid 34693604)
44. Saito I, Asano T, Sano K, Takakura K, Abe H, Yoshimoto T, et al. Neuroprotective effect of an antioxidant, ebselen, in patients with delayed neurological deficits after aneurysmal subarachnoid hemorrhage. Neurosurgery 1998;42:269-77.
45. Bardia A, Platz EA, Yegnasubramanian S, De Marzo AM, Nelson WG. Anti-inflammatory drugs, antioxidants, and prostate cancer prevention. Curr Opin Pharmacol 2009;9:419-26.
46. Yamaguchi T, Sano K, Takakura K, Saito I, Shinohara Y, Asano T, Yasuhara H. Ebselen in acute ischemic stroke: a placebo-controlled, double-blind clinical trial. Stroke 1998;29:12-7. (Pubitemid 28046934)
47. Zhang D, Shao J, Lin J, Zhang N, Lu BJ, Lin SC, et al. RIP3, an energy metabolism regulator that switches death from apoptosis to necrosis. Science 2009;325:332-6.
48. Parnham M, Biedermann J, Bittner C, Dereu N, Leyck S, Wetzig H. Structure-activity relationships of a series of anti-inflammatory benzisoselenazolones (BISAs). Agents Actions 1989;27:306-8. (Pubitemid 19188627)